Clinical Trials Logo

Filter by:
NCT ID: NCT04640285 Completed - Clinical trials for Electronic Cigarette Use

Nicotine Uptake, Measures of Abuse Liability, and Puffing Topography With Use of RELX ENDS Products by Smokers

Start date: November 3, 2020
Phase: N/A
Study type: Interventional

This study is being conducted to evaluate nicotine uptake and exposure, the abuse liability, and puffing topography associated with the use of an electronic nicotine delivery system ENDS with tobacco- and menthol-flavored e-liquids in current smokers.

NCT ID: NCT04640272 Completed - Clinical trials for Exudative Age-related Macular Degeneration

A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration

RAMEN
Start date: November 3, 2020
Phase: Phase 2
Study type: Interventional

This is a multi-center, open label, extension study of NCT04200248 assessing the efficacy and safety of additional intravitreal injections of RBM-007 in subjects with wet age-related macular degeneration.

NCT ID: NCT04640207 Completed - Rejuvenation Clinical Trials

The Efficacy of the Alma Hybrid System for a New Approach of Facial Skin Treatment

Start date: November 25, 2020
Phase: N/A
Study type: Interventional

The study is aimed to evaluate the efficacy of the Alma Hybrid system for a new approach of facial skin treatment, using both ablative and non-ablative wavelengths. The study will include 20 subjects with mild-moderate photodamaged skin, that will undergo 2 facial skin treatments. Follow up visit to evaluate the efficacy of the treatments will take place 1 and 3 months after the last treatment.

NCT ID: NCT04640181 Completed - Covid19 Clinical Trials

Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)

XACT
Start date: December 1, 2020
Phase: Phase 2
Study type: Interventional

This study is a multicenter, randomized trial to study the potential benefit of treatments with a direct FXa inhibitor (rivaroxaban) versus standard of care dose subcutaneous low molecular weight heparin (LMWH) (Lovenox) in hospitalized subjects with COVID-19.

NCT ID: NCT04640168 Completed - COVID-19 Clinical Trials

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

Start date: December 2, 2020
Phase: Phase 3
Study type: Interventional

ACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone and remdesivir. Subjects will be assessed daily while hospitalized. If the subjects are discharged from the hospital, they will have a study visit at Days 15, 22, and 29. For discharged subjects, it is preferred that the Day 15 and 29 visits are in person to obtain safety laboratory tests, oropharyngeal (OP) swabs, plasma (Day 29), and serum for secondary research as well as clinical outcome data. However, if infection control or other restrictions limit the ability of the subject to return to the clinic, these visits may be conducted by phone, and only clinical data will be obtained. The Day 22 visit does not have laboratory tests or collection of samples and is conducted by phone. The primary objective is to evaluate the clinical efficacy of baricitinib + remdesivir versus dexamethasone + remdesivir as assessed by the mechanical ventilation free survival by Day 29.

NCT ID: NCT04640090 Completed - Depression Clinical Trials

Wellness Through Mobile Health

Start date: August 12, 2020
Phase: N/A
Study type: Interventional

This pilot project will evaluate the potential of an affordable smartphone app to improve users' mental well-being.

NCT ID: NCT04640077 Completed - Alzheimer Disease Clinical Trials

A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

Start date: November 23, 2020
Phase: Phase 2
Study type: Interventional

The main goals of this study are to further determine whether the study drug donanemab is safe and effective in participants with Alzheimer's disease and to validate video scale assessments.

NCT ID: NCT04640038 Completed - Covid19 Clinical Trials

Contrast Enhanced Ultrasound in COVID-19

Start date: December 18, 2020
Phase: Phase 3
Study type: Interventional

Initial data from COVID-19 patients suggests that one of the primary causes of death is significant endothelial injury leading to blood clotting and impaired multiorgan microvascular perfusion. The current study uses a safe, convenient bedside imaging tool called contrast-enhanced ultrasound (CEUS) to estimate the extent of microvascular perfusion impairment in the heart, kidneys and/or brain of COVID-19 pediatric patients in vivo and assess the significance of imaging findings by correlating to clinical outcomes. This pilot study will be conducted at one site, The Children's Hospital of Philadelphia. The investigators plan to enroll and evaluate 30 patients.

NCT ID: NCT04639973 Completed - Obesity Clinical Trials

Early Anatomy Scan for Evaluation of Obese Pregnant Women (EASE-O)

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the feasibility of ultrasound in the first trimester, assess the completion rate of ultrasounds for fetal anatomy in the first trimester compared to completion rates of ultrasounds for fetal anatomy in the second trimester and to assess the completion rate of the combination of one ultrasound in the first trimester and one in the second trimesters compared to the individual completion rates of both evaluations in obese pregnant women.

NCT ID: NCT04639882 Completed - Heavy Drinking Clinical Trials

Motivating Recruitment and Efficacy in Normative Feedback Interventions

Start date: September 10, 2014
Phase: N/A
Study type: Interventional

Excessive alcohol consumption among college students continues to be a serious public health concern associated with a wide range of negative consequences. Brief computer-based social norms interventions, including personalized normative feedback (PNF), have shown consistent effects in reducing problematic drinking in this population, and there is some evidence that in-lab computer-delivered interventions may be more effective than remote interventions. Most studies have been conducted using generous incentives which may reduce the feasibility of dissemination on a larger scale and may undermine trial efficacy. In accordance with NIAAA aims, this research aims to (a) investigate delivery modality (i.e., in lab versus remotely) and incentives as important factors affecting the efficacy of PNF interventions and (b) develop intervention strategies that facilitate wider dissemination of inexpensive empirically-supported brief interventions for college students, thereby reducing problem drinking during a high-risk time period.